Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

23.00 +0.17 (+0.74%)
Official Closing Price Updated: 7:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Should You Buy Pfizer Stock Right Now in 2025?
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025
Three high-octane income stocks -- sporting an average yield of 7.93% -- can fatten investors' pocketbooks in the new year. 
Via The Motley Fool
10 Magnificent Stocks That Can Make You Richer in 2025
A new year brings with it new opportunities to grow your wealth on Wall Street. 
Via The Motley Fool
Got $5,000? These 3 Stocks Are Absurdly Cheap Buys Heading Into 2025
Via The Motley Fool
Top 3 Stocks Seeing a Spike in Call Option Volume
Three stocks reported unusual call option volume this month, and the reasons why would make sense to all investors and Wall Street analysts. 
Via MarketBeat
Topics ETFs
How Is The Market Feeling About Pfizer?
Via Benzinga
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
Via The Motley Fool
10 Stock Market Predictions for 2025
Here's what to expect from the stock market, along with some of Wall Street's hottest trends and most influential businesses, in the new year. 
Via The Motley Fool
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Higher; House Prices Increase In October
Via Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
Via Benzinga
Better Income Stock: Pfizer or Altria Group?
Via The Motley Fool
This Is What Whales Are Betting On Pfizer
Via Benzinga
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
The beaten-down pharmaceutical giant could double your investment over three to four years. 
Via The Motley Fool
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca 
Via MarketBeat
Exposures COVID-19
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious
Sangamo intends to explore all options to advance the program, 
Via Stocktwits
5 Unbeatable Stocks I'm Eager to Buy in 2025
These value, growth, and income stocks are incredibly cheap in a historically pricey stock market. 
Via The Motley Fool
My 5 Favorite Ultra-High-Yield Dividend Stocks to Buy for 2025
Via The Motley Fool
360 Stocks in the S&P 500 Underperformed the Benchmark's 2024 Gain of 24%. Here's 2 High-Yielding S&P 500 Stocks to Buy in 2025, According to Wall Street.
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Overlooked Stocks Set to Soar in 2025
All 10 underperformed in 2024, but I believe they'll turn things around in 2025. 
Via The Motley Fool
Stocks Going Ex Dividend In January 2025
The following is a short list of some of the many stocks going ex-dividend during the next month. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
4 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025. 
Via Benzinga
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
Via The Motley Fool
Topics ETFs
Stocking Stuffers for Income Investors: 3 Ultra-High-Yield Dividend Stocks to Buy Before the End of 2024
Via The Motley Fool
Pfizer: Guidance Reaffirmed, Nice Yield. What's Not To Like?
Pfizer Inc. recently released its full-year 2025 guidance and reaffirmed its 2024 outlook, aligning with Street expectations. It seems having faith in the company may have paid off. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.